In a preclinical study using a murine ovarian cancer model, the combination of a GITR agonist and a PD-1 inhibitor reduced peritoneal tumour growth by increasing the responses of memory T-cells cells against tumour cells, increased frequencies of IFN-γ-producing effector T-cells and suppressed Tregs and MDSC [106]. Here, PDCD1 is linked to neoplasm.